环己基三苯基溴化膦 | 7333-51-9

• 物质功能分类: 有机原料 - 有机膦化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 环己基三苯基溴化膦
• 中文别名: 环己基三苯基溴化磷鎓
• 英文名称: cyclohexyl(triphenyl)phosphonium bromide
• 英文别名: Cyclohexyltriphenylphosphonium bromide；cyclohexyl(triphenyl)phosphanium;bromide
• CAS: 7333-51-9
• 化学式: Br*C₂₄H₂₆P
• 分子量: 425.348
• InChiKey: QRAKRDZMIONMRZ-UHFFFAOYSA-M

物化性质

• 熔点：
  265-272 °C
• 稳定性/保质期：
  如果遵照规格使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.32
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT, HYGROSCOPIC
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  29310099
• 储存条件：
  密封存储在阴凉干燥的环境中。

SDS

Name:	Cyclohexyltriphenylphosphonium Bromide 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	7333-51-9

Section 1 - Chemical Product MSDS Name:Cyclohexyltriphenylphosphonium Bromide 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
7333-51-9	Cyclohexyltriphenylphosphonium Bromide	97%	230-834-2

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.Hygroscopic (absorbs moisture from the air).
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store protected from moisture.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 7333-51-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 270 - 272 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C24H26BrP
Molecular Weight: 425.34

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, exposure to moist air or water.
Incompatibilities with Other Materials:
Oxidizing agents, strong bases, strong acids.
Hazardous Decomposition Products:
Carbon monoxide, oxides of phosphorus, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 7333-51-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Cyclohexyltriphenylphosphonium Bromide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 7333-51-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 7333-51-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 7333-51-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  环己基三苯基溴化膦 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 17.0h， 生成 1-bromo-4-(cyclohexylidenemethyl)benzene
  参考文献：
  名称：

  银催化的高取代苯乙烯的加氢芳基化

  摘要：

  加氢芳基化是一种有效的策略，可通过将平面烯烃部分转化为三维框架来快速增加有机结构的复杂性。已经开发出许多策略来实现苯乙烯的加氢芳基化，然而，大多数这些报告在主要研究富含电子的苯亲核试剂的同时，研究了非极性，β-单取代或β-未取代的苯乙烯的加氢芳基化。在本文中，我们报道了一种温和而通用的催化体系，用于多取代苯乙烯和杂芳族苯乙烯的选择性加氢杂芳基化。反应的机理分析导致发现了市售的2,2'：5'，2''-噻吩作为关键试剂。

  DOI：

  10.1002/anie.202016268
• 作为产物：
  描述：

  溴代环己烷 、 三苯基膦 以 甲苯 为溶剂， 反应 48.0h， 以80%的产率得到环己基三苯基溴化膦
  参考文献：
  名称：

  均相和多相 Pd 催化选择性 C-P 活化和转移氢化用于“基团取代”合成三价膦

  摘要：

  报道了通过鏻盐的 C-P 活化合成三价膦的“基团取代”。通过膦的烷基化引入烷基以形成鏻盐。鏻盐的“去芳基化”是通过 C-P 活化和使用均相或非均相 Pd (0) 催化剂的转移氢化来实现的。采用这种方法，从市售的三芳基膦中制备了一系列三价膦。手性单膦配体可以从 BINAP 在“脱膦”过程中制备。

  DOI：

  10.1021/acs.orglett.2c00844
• 作为试剂：
  描述：

  二氢可待因酮 在 potassium tert-butylate 、 环己基三苯基溴化膦 作用下， 生成 (1R,5R,6S,10R,18R,24R,25R)-15,30-dimethoxy-9,35-dimethyl-17,20-dioxa-9,35-diazadecacyclo[23.7.3.16,12.01,24.02,21.03,19.05,10.06,18.027,32.016,36]hexatriaconta-3(19),12(36),13,15,27(32),28,30-heptaene-21,31-diol
  参考文献：
  名称：

  Liu, Maxson; Mahon, Mary F.; Sainsbury, Malcolm, Journal of the Chemical Society. Perkin transactions I, 1998, # 17, p. 2943 - 2951

  摘要：

  DOI：

文献信息

• Catalytic, Diastereoselective 1,2-Difluorination of Alkenes
  作者：Steven M. Banik、Jonathan William Medley、Eric N. Jacobsen

  DOI：10.1021/jacs.6b02391

  日期：2016.4.20

  with all types of substitution patterns. In general, the vicinal difluoride products are produced with high diastereoselectivities. The observed sense of stereoinduction implicates anchimeric assistance pathways in reactions of alkenes bearing neighboring Lewis basic functionality.

  我们描述了一种直接催化烯烃 1,2-二氟化的方法。该方法利用亲核氟化物源和氧化剂以及芳基碘化物催化剂，适用于具有所有类型取代模式的烯烃。一般来说，邻位二氟化物产物具有高非对映选择性。观察到的立体诱导感暗示具有邻近路易斯基本官能团的烯烃反应中的嵌合辅助途径。
• Ni-Catalyzed Arylboration of Unactivated Alkenes: Scope and Mechanistic Studies
  作者：Stephen R. Sardini、Alison L. Lambright、Grace L. Trammel、Humair M. Omer、Peng Liu、M. Kevin Brown

  DOI：10.1021/jacs.9b03991

  日期：2019.6.12

  unactivated monosubstituted, 1,1-disubstituted, and trisubstituted alkenes is disclosed. The reaction is notable in that it converts highly substituted alkenes, aryl bromides, and diboron reagents to products that contain a quaternary carbon and a synthetically versatile carbon-boron bond with control of stereoselectivity and regioselectivity. In addition, the method is demonstrated to be useful for the

  公开了一种未活化的单取代、1,1-二取代和三取代烯烃的Ni催化芳基硼化反应的方法。该反应的值得注意之处在于，它将高度取代的烯烃、芳基溴和二硼试剂转化为含有季碳和合成通用碳硼键的产物，并控制立体选择性和区域选择性。此外，该方法被证明可用于合成饱和氮杂环，这是药物化合物中的重要基序。最后，由于所表现出的不寻常的反应性，我们通过计算和实验技术研究了反应的机理细节。
• 一种腈基二苯基硫代乙酸结构的P2Y12受体 拮抗剂及其用途
  申请人：天津小新医药科技有限公司

  公开号：CN108129370B

  公开（公告）日：2021-06-29

  本发明涉及与心血管疾病相关的药物领域。具体而言，本发明涉及一种含腈基二苯基硫代乙酸结构的P2Y12受体拮抗剂、其制备方法及其在制备治疗心血管疾病尤其是血栓栓塞性疾病药物中的应用。
• Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
  申请人：——

  公开号：US20030225142A1

  公开（公告）日：2003-12-04

  Compounds for treating abuse of nicotinic receptor agonists, addiction to psychostimulant drugs, addiction to opiates, addiction to alcohol, addiction to tobacco products, addiction to nicotine, schizophrenia and related diseases, depression and related conditions, Alzheimer's disease, Parkinson's disease, irritable bowel syndrome, and colitis. The compounds competitively inhibit central nervous system acting nicotinic receptor agonists and act at the putative &agr;3&bgr;2* and &agr;4&bgr;2 neuronal nicotinic receptors in the central nervous system.

  用于治疗尼古丁受体激动剂滥用、对精神刺激药物上瘾、对阿片类药物上瘾、对酒精上瘾、对烟草制品上瘾、对尼古丁上瘾、精神分裂症及相关疾病、抑郁症及相关症状、阿尔茨海默病、帕金森病、肠易激综合征和结肠炎的化合物。这些化合物竞争性地抑制中枢神经系统作用的尼古丁受体激动剂，并在中枢神经系统中的假定的α3β2*和α4β2神经元尼古丁受体起作用。
• [EN] VITAMIN D ANALOGUES, COMPOSITIONS COMPRISING SAID ANALOGUES AND THEIR USE<br/>[FR] ANALOGUES DE LA VITAMINE D, COMPOSITIONS COMPRENANT LESDITS ANALOGUES ET LEUR UTILISATION
  申请人：LEO PHARMA AS

  公开号：WO2004037781A1

  公开（公告）日：2004-05-06

  Compounds according to formula I: in which formula R1 and R2, which may be the same or different, represent halogen, (C1-C6) hydrocarbyl, optionally substituted with one or two hydroxyl group on one or more fluorine atoms, or, together with the carbon atom to which they are both attached, R1 and R2 form a (C3-C6)carbocyclic ring, or one of R1 and R2 taken together with R3 forms a direct bond, such that a triple bond is constituted, or R1 and R2 represent both hydrogen; R3 when not forming a direct bond with one of R1 and R2 represents hydrogen or (C1-C3)hydrocarbyl; X represents (E)-ethylene, (Z)-ethylene, ethynylene, or a bond; Y and Z independently represent hydrogen or methyl; the bond between C#16 and C#17 is depicted with a dotted line to illustrate that said bond may be either a single bond, in which case the projection of the ring substituents is beta, or a double bond; A represents hydroxyl, fluorine or hydrogen; B represents CH2 or H2; the configuration is the 3-position corresponds to the same configuration as in natural vitamine D3 (normal), or the configuration in the configuration in the 3-position is opposite to that of natural vitamin D3(epi); with the proviso that when X represents (E)-ethylene or (Z)-ethylene, one of R1 and R2 taken together with R3 may not form a direct bond, such that a triple bond is constituted; with the further proviso that when X represents a bond R1 ands R2 are nor hydrogen; with the further proviso that the compound of formula I is not 3(S)-hyroxy-9, 10-secocholesta-5(Z),7(E),10(19),22(E),24-penta-ene; and prodrugs and stereo isomeric forms thereof are provided together with their use in therapy, and their use in the manufacture of medicaments.

  根据公式I：其中公式中的R1和R2，可以相同也可以不同，代表卤素，(C1-C6)烃基，可选地在一个或多个氟原子上用一个或两个羟基取代，或者，与它们都连接的碳原子一起，R1和R2形成一个(C3-C6)碳环，或者R1和R2中的一个与R3一起形成直接键，从而构成三键，或者R1和R2都代表氢；当R3不与R1和R2中的一个形成直接键时，代表氢或(C1-C3)烃基；X代表(E)-乙烯，(Z)-乙烯，乙炔基，或者一个键；Y和Z独立地代表氢或甲基；C#16和C#17之间的键用虚线表示，以说明该键可以是单键，此时环取代基的投影为β，或者是双键；A代表羟基，氟或氢；B代表CH2或H2；3位的构型与天然维生素D3 (正常)中的构型相对应，或者3位的构型与天然维生素D3 (epi)中的构型相反；但是当X代表(E)-乙烯或(Z)-乙烯时，R1和R2中的一个与R3一起不能形成直接键，从而构成三键；进一步的条件是，当X代表一个键时，R1和R2不是氢；进一步的条件是，公式I的化合物不是3(S)-羟基-9,10-去甲胆骨化甾-5(Z),7(E),10(19),22(E),24-五烯；还提供了它们的前药和立体异构体形式，以及它们在治疗中的用途，以及它们在药物制造中的用途。